NASDAQ:RVNC - Revance Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.83
  • Forecasted Upside: 30.55 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$25.15
▼ -0.65 (-2.52%)
1 month | 3 months | 12 months
Get New Revance Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVNC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVNC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.83
▲ +30.55% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Revance Therapeutics in the last 3 months. The average price target is $32.83, with a high forecast of $45.00 and a low forecast of $15.00. The average price target represents a 30.55% upside from the last price of $25.15.
Buy
The current consensus among 7 investment analysts is to buy stock in Revance Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $35.00Low
i
2/23/2021MizuhoBoost Price TargetPositive ➝ Buy$30.00 ➝ $33.00High
i
2/23/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $35.00High
i
1/8/2021Needham & Company LLCBoost Price TargetBuy$42.00 ➝ $45.00High
i
11/10/2020MizuhoLower Price TargetBuy$32.00 ➝ $30.00High
i
Rating by Difei Yang at Mizuho
10/26/2020BarclaysBoost Price TargetOverweight$35.00 ➝ $38.00Medium
i
10/15/2020Needham & Company LLCBoost Price TargetBuy$36.00 ➝ $42.00Low
i
10/15/2020HC WainwrightBoost Price TargetBuy$27.00 ➝ $33.00Low
i
Rating by Douglas Tsao at HC Wainwright
9/28/2020BarclaysBoost Price TargetOverweight$32.00 ➝ $35.00Low
i
8/11/2020MizuhoInitiated CoverageBuy$32.00Low
i
Rating by Difei Yang at Mizuho
7/10/2020HC WainwrightReiterated RatingBuy$27.00Medium
i
Rating by Douglas Tsao at HC Wainwright
6/2/2020HC WainwrightReiterated RatingBuy$24.00Medium
i
Rating by Douglas Tsao at HC Wainwright
5/20/2020MizuhoReiterated RatingBuy$35.00Low
i
4/16/2020Stifel NicolausLower Price TargetBuy$35.00 ➝ $31.00High
i
4/15/2020Needham & Company LLCReiterated RatingBuy$36.00High
i
4/1/2020MizuhoReiterated RatingBuy$39.00 ➝ $35.00High
i
3/27/2020William BlairReiterated RatingBuyMedium
i
3/27/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $24.00Medium
i
Rating by D. Tsao at HC Wainwright
3/22/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$32.00 ➝ $15.00Medium
i
Rating by Terence Flynn at The Goldman Sachs Group, Inc.
2/26/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00Low
i
Rating by Douglas Tsao at HC Wainwright
2/25/2020Piper SandlerBoost Price TargetOverweight$37.00 ➝ $40.00High
i
2/25/2020Needham & Company LLCBoost Price TargetBuy$32.00 ➝ $36.00High
i
2/18/2020Piper SandlerLower Price TargetOverweight$38.00 ➝ $37.00Low
i
1/23/2020MizuhoBoost Price TargetBuy ➝ Positive$34.00 ➝ $39.00Low
i
12/2/2019The Goldman Sachs GroupInitiated CoverageBuy$25.00High
i
11/5/2019MizuhoReiterated RatingBuy$34.00High
i
10/30/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$12.50 ➝ $20.00High
i
10/15/2019HC WainwrightSet Price TargetBuy$23.00Medium
i
Rating by Douglas Tsao at HC Wainwright
10/14/2019MizuhoReiterated RatingBuy$34.00High
i
8/6/2019William BlairReiterated RatingOutperformHigh
i
Rating by T. Lugo at William Blair
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$28.00Medium
i
4/24/2019MizuhoReiterated RatingBuy$37.00Medium
i
3/1/2019SunTrust BanksLower Price TargetPositive ➝ Buy$29.00High
i
2/27/2019MizuhoReiterated RatingBuyHigh
i
2/15/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$17.83Low
i
2/14/2019HC WainwrightInitiated CoverageBuy$25.00Low
i
Rating by D. Tsao at HC Wainwright
1/28/2019Stifel NicolausInitiated CoverageBuy$50.00High
i
1/18/2019MizuhoReiterated RatingBuyMedium
i
11/16/2018GuggenheimUpgradeNeutral ➝ Buy$41.00Low
i
11/1/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
9/17/2018Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by David Amsellem at Piper Jaffray Companies
9/17/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
9/14/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/2/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
5/29/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
5/8/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
4/20/2018GuggenheimReiterated RatingHoldHigh
i
4/20/2018MizuhoLower Price TargetBuy$54.00 ➝ $48.00High
i
4/2/2018Cantor FitzgeraldReiterated RatingBuy$50.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
3/26/2018Needham & Company LLCInitiated CoverageBuy$42.00Low
i
3/5/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$60.00Medium
i
Rating by Dana Flanders at The Goldman Sachs Group, Inc.
3/1/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00High
i
Rating by David Amsellem at Piper Jaffray Companies
3/1/2018William BlairReiterated RatingOutperformMedium
i
2/28/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
1/17/2018CowenSet Price TargetBuy$55.00Low
i
Rating by Ken Cacciatore at Cowen Inc
1/9/2018GuggenheimDowngradeBuy ➝ HoldN/A
i
1/5/2018MizuhoReiterated RatingBuy$54.00Low
i
1/4/2018GuggenheimReiterated RatingBuy ➝ Neutral$42.00High
i
1/4/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
12/19/2017BarclaysSet Price TargetOverweight ➝ Buy$40.00High
i
Rating by Douglas Tsao at Barclays PLC
12/13/2017Cantor FitzgeraldSet Price TargetBuy$50.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
12/8/2017SunTrust BanksBoost Price TargetBuy$53.00Medium
i
12/6/2017MizuhoBoost Price TargetBuy ➝ Buy$37.00 ➝ $54.00Medium
i
12/5/2017GuggenheimInitiated CoverageBuy ➝ Buy$42.00Medium
i
12/5/2017Piper Jaffray CompaniesBoost Price TargetPositive ➝ Overweight$28.00 ➝ $51.00High
i
Rating by David Amsellem at Piper Jaffray Companies
12/5/2017Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
11/29/2017Cantor FitzgeraldSet Price TargetBuy$50.00High
i
Rating by Louise Chen at Cantor Fitzgerald
11/27/2017BarclaysInitiated CoverageOverweight$31.00Medium
i
Rating by Douglas Tsao at Barclays PLC
11/16/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
11/16/2017MizuhoInitiated CoverageBuy ➝ Buy$37.00N/A
i
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$28.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
10/24/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/A
i
9/26/2017Cantor FitzgeraldReiterated RatingBuy$50.00High
i
9/6/2017Cantor FitzgeraldReiterated RatingBuy$50.00Low
i
8/22/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$34.00Medium
i
7/26/2017Piper Jaffray CompaniesSet Price TargetBuy$28.00Low
i
7/20/2017Cantor FitzgeraldInitiated CoverageOverweight$50.00High
i
6/8/2017AegisReiterated RatingBuy$36.00Medium
i
Rating by Difei Yang at Aegis
5/19/2017AegisReiterated RatingBuy$28.00 ➝ $36.00Low
i
Rating by Difei Yang at Aegis
5/1/2017AegisReiterated RatingBuy$28.00High
i
Rating by Difei Yang at Aegis
2/28/2017AegisReiterated RatingBuy$28.00N/A
i
Rating by Difei Yang at Aegis
1/19/2017AegisReiterated RatingBuy$28.00N/A
i
Rating by Difei Yang at Aegis
1/8/2017AegisSet Price TargetBuy$28.00N/A
i
Rating by Difei Yang at Aegis
11/29/2016AegisInitiated CoverageBuy$28.00N/A
i
8/5/2016Brean CapitalReiterated RatingHoldN/A
i
Rating by Difei Yang at Brean Capital
6/23/2016Brean CapitalReiterated RatingHoldN/A
i
Rating by Difei Yang at Brean Capital
6/14/2016SunTrust BanksLower Price TargetBuy$46.00 ➝ $22.00N/A
i
6/14/2016Brean CapitalDowngradeBuy ➝ HoldN/A
i
Rating by Difei Yang at Brean Capital
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$54.00 ➝ $35.00N/A
i
6/14/2016GuggenheimReiterated RatingBuy$55.00N/A
i
Rating by Louise Chen at Guggenheim
6/4/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Difei Yang at Brean Capital
5/24/2016Brean CapitalReiterated RatingBuy$48.00N/A
i
Rating by Difei Yang at Brean Capital
5/10/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Difei Yang at Brean Capital
4/11/2016GuggenheimReiterated RatingBuy$55.00N/A
i
Rating by Louise Chen at Guggenheim
3/23/2016SunTrust BanksInitiated CoverageBuy$46.00N/A
i
3/16/2016Brean CapitalInitiated CoverageBuy$48.00N/A
i
3/4/2016GuggenheimReiterated RatingBuy$55.00N/A
i
(Data available from 3/4/2016 forward)
Revance Therapeutics logo
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Read More

Today's Range

Now: $25.15
$24.94
$25.80

50 Day Range

MA: $27.88
$25.35
$29.97

52 Week Range

Now: $25.15
$11.78
$34.62

Volume

13,753 shs

Average Volume

450,271 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Revance Therapeutics?

The following Wall Street sell-side analysts have issued reports on Revance Therapeutics in the last year: Barclays PLC, HC Wainwright, Mizuho, Needham & Company LLC, Stifel Nicolaus, The Goldman Sachs Group, Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for RVNC.

What is the current price target for Revance Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Revance Therapeutics in the last year. Their average twelve-month price target is $32.83, suggesting a possible upside of 26.0%. Needham & Company LLC has the highest price target set, predicting RVNC will reach $45.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $15.00 for Revance Therapeutics in the next year.
View the latest price targets for RVNC.

What is the current consensus analyst rating for Revance Therapeutics?

Revance Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVNC will outperform the market and that investors should add to their positions of Revance Therapeutics.
View the latest ratings for RVNC.

What other companies compete with Revance Therapeutics?

How do I contact Revance Therapeutics' investor relations team?

Revance Therapeutics' physical mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company's listed phone number is 510-742-3400 and its investor relations email address is [email protected] The official website for Revance Therapeutics is www.revance.com.